SAN DIEGO--(BUSINESS WIRE)--March 28, 2006--Earlier this year, Optimer Pharmaceuticals, Inc., opened an IND (Investigational New Drug) with the Food and Drug Administration, for its late-stage anti-infective compound, OPT-99. Phase 3 clinical trials of OPT-99 for bacterial gastroenteritis are scheduled to begin in May 2006.
